glp-1 receptor agonists dizziness side effect Frontiers GLP-1: Genetic Variants Related to

Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials

doi: 10.1016/j.cmet.2018.01.005

doi: 10.1016/j.brainresbull.2011.10.004

Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements

Atherosclerotic CVD manifest as heart attacks and strokes, is responsible for up to 85 per cent of cardiovascular deaths [1]

Glucagon Physiology